Global InformationTexaphyrin information
Texaphyrin is a sub-class of heterocyclic macrocycle molecules known as porphyrins. The molecule was invented by University of Texas at Austin professor Jonathan Sessler. The name texaphryin arose because some of the molecules have a shape that can superimpose onto the points of the star featured on the state flag of Texas.[1] Texaphyrins were nominated as the "State Molecule of Texas", but the buckyball was chosen instead.[2]
Sessler has described possible medicinal uses of these compounds in the Proceedings of the National Academy of Sciences and other scientific journals. Pharmacyclics, Inc., a publicly traded company begun by Sessler, licensed the technology behind texaphyrins from the university to develop commercial and medical uses for the molecules. Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc. It is a photosensitiser for use in photodynamic therapy to treat skin conditions and Prostate cancer.[4] Pharmacyclics and the rights to texaphyrins was sold to AbbVie in 2015 for 21 billion dollars.[5]
- ^ Adams, A. (1998). "AAAS MEETING:10-Gallon Molecule Stomps Tumors". Science. 279 (5355): 1307b–1308. doi:10.1126/science.279.5355.1307b. PMID 9508706. S2CID 12961805.
- ^ Texas Legislature resolution, 1997
- ^ Preihs, Christian; Arambula, Jonathan F.; Magda, Darren; Jeong, Heeyeong; Yoo, Dongwon; Cheon, Jinwoo; Siddik, Zahid H.; Sessler, Jonathan L. (April 4, 2013). "Recent Developments in Texaphyrin Chemistry and Drug Discovery". Inorg. Chem. 52 (21): 12184–12192. doi:10.1021/ic400226g. PMC 3963820. PMID 23557113.
- ^ Hiral, Patel; Rosemarie, Mick (August 2008). "Motexafin Lutetium-Photodynamic Therapy of Prostate cancer: Short- and Long-Term Effects on Prostate-Specific Antigen". Clinical Cancer Research. 14 (15): 4869–4876. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.
- ^ "AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise | AbbVie News Center". news.abbvie.com. Retrieved 2023-06-09.